mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The CDC currently estimates the prevalence of autism spectrum disorders (ASD) at 1 in 88 children. Though the exact etiology of ASD is unknown, recent studies implicate synaptic maturation and plasticity in the pathogenesis of ASD leading to an imbalance of excitation and inhibition, and specifically a disproportionately high level of excitation. Pharmacological agents that modulate excitation and inhibition are currently in clinical trials for treatment of ASD and show promising preliminary results. AREAS COVERED: This paper reviews the literature implicating the role of glutamate and GABA pathways in the pathophysiology of ASD. It also provides a review of the current results from both animal models and human clinical trials of drugs aimed at normalizing the imbalance of excitation and inhibition through the use of metabotropic glutamate receptor (mGluR) antagonists and GABA agonists. EXPERT OPINION: Both mGluR antagonists and GABA agonists have promising preliminary data from animal model and small-scale Phase II human trials. They show significant efficacy in subpopulations and appear to have favorable side-effect profiles. Though preliminary data are extremely promising, results from ongoing larger, double-blind, placebo-controlled studies will give a more complete understanding of the efficacy and side-effect profile related to these drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model of autism: increased ratio of excitation/inhibition in key neural systems
Rubenstein, J. L. R., & Merzenich, M. M. (2003) · Genes, Brain and Behavior · doi:10.1034/j.1601-183x.2003.00037.x · Cited by 2,768 · cited 2×
“The specific pathology of synapse maturation and plasticity during development seen in ASD is thought to lead to an imbalance of excitation and inhibition, and specifically a disproportionately high level of excitation [5].”
BackgroundNeocortical excitation/inhibition balance in information processing and social dysfunction
Yizhar, O., Fenno, L. E., Prigge, M., Schneider, F., Davidson, T. J., O’Shea, D. J., Sohal, V. S., Goshen, I., Finkelstein, J., Paz, J. T., et al. (2011) · Nature · doi:10.1038/nature10360 · Cited by 2,454 · cited 1×
“Additionally, recent animal studies suggest that a modulation in this balance toward excitation in the mouse medial prefrontal cortex resulted in autistic-like behaviors and subsequent compensatory elevation of inhibitory factors partially rescued the social deficits caused by the excitation/inhibition imbalance [7].”
BackgroundDysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes
Chao, H.-T., Chen, H., Samaco, R. C., Xue, M., Chahrour, M., Yoo, J., Neul, J. L., Gong, S., Lu, H.-C., Heintz, N., et al. (2010) · Nature · doi:10.1038/nature09582 · Cited by 1,168
Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008) · Nature Medicine · doi:10.1038/nm1788 · Cited by 882 · cited 1×
“Similarly, in TSC2 mouse models, mTOR antagonists rescued not only the synaptic plasticity, but also spatial learning and contextual discrimination deficits [35].”
BackgroundMinicolumnar pathology in autism
Casanova, M. F., Buxhoeveden, D. P., Switala, A. E., & Roy, E. (2002) · Neurology · doi:10.1212/wnl.58.3.428 · Cited by 846
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · cited 1×
“However, post hoc analysis revealed that the seven patients with fully methylated mutations showed significant improvements in the Aberrant Behavior Checklist (ABC), Clinical Global Impression Scale and the Social Responsiveness Scale as well as specific improvements in subscales measuring stereotypic behavior, hypera…”
The Autistic Neuron: Troubled Translation?
Kelleher, R. J., & Bear, M. F. (2008) · Cell · doi:10.1016/j.cell.2008.10.017 · Cited by 598 · cited 1×
“of ASD have found that the loss of the associated proteins resulted in an increase in mGluR-mediated synaptic protein synthesis, however in some models, specifically those for Rett’s syndrome and TSC1 and TSC2, it appears that the loss of the protein results in a decrease in mGluR-mediated synaptic protein synthesis a…”
ResultFatemi, S. H., Halt, A. R., Stary, J. M., Kanodia, R., Schulz, S. C., & Realmuto, G. R. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01430-0 · Cited by 500
Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
Silverman, J. L., Tolu, S. S., Barkan, C. L., & Crawley, J. N. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.201 · Cited by 438 · cited 1×
“Results indicate that the animals showed reduced self-grooming behavior (a putative analog to the excessive stereotypic behaviors seen in humans with ASD) [29,30] and improvement in one index of social interaction (time spent sniffing an enclosed social stimulus mouse).”
BackgroundNeural Plasticity: The Effects of Environment on the Development of the Cerebral Cortex
Huttenlocher, P. R. (2002) · doi:10.4159/9780674038936 · Cited by 421
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 1×
“After a single dose of the drug, 50% of the patients showed improved eye contact and 25% showed improvements in social interaction [36].”
BackgroundHussman, J. P. (2001) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1010715619091 · Cited by 263 · cited 1×
“The GABAergic system has been suggested to be a key player in the etiology of both idiopathic and syndromic forms of ASD [14-16].”
BackgroundSilverman, J. L., Smith, D. G., Rizzo, S. J. S., Karras, M. N., Turner, S. M., Tolu, S. S., Bryce, D. K., Smith, D. L., Fonseca, K., Ring, R. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003501 · Cited by 251
Plasma amino acid levels in children with autism and their families
Aldred, S., Moore, K. M., Fitzgerald, M., & Waring, R. H. (2003) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1022238706604 · Cited by 188 · cited 1×
“Studies have shown increased levels of glutamate in both the blood and platelets of individuals with ASD [10,11].”
BackgroundPacey, L. K. K., Heximer, S. P., & Hampson, D. R. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056127 · Cited by 133 · cited 1×
“Similarly in FXS mouse models, treatment with GABAB agonist STX209 (arbaclofen, active enantiomer of baclofen (Seaside Therapeutics)) resulted in reduced audiogenic seizures [39] and normalized behavioral phenotypes including marble burying (Seaside Therapeutics, unpublished) and hyperactivity [40].”
BackgroundNeuronal Density and Architecture (Gray Level Index) in the Brains of Autistic Patients
Casanova, M. F., Buxhoeveden, D. P., Switala, A. E., & Roy, E. (2002) · Journal of Child Neurology · doi:10.1177/088307380201700708 · Cited by 121 · cited 1×
“In this regard, it is worth pointing out that abnormalities in GABAergic interneurons have been associated with narrowing of cell minicolumns [19] a neuropathological finding noted in brains of patients with ASD [20,21].”
BackgroundThe neurochemical basis for the treatment of autism spectrum disorders and Fragile X syndrome
Hampson, D. R., Adusei, D. C., & Pacey, L. K. K. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.02.005 · Cited by 34
Cited by
GABAergic Signaling as Therapeutic Target for Autism Spectrum Disorders
Cellot, G., & Cherubini, E. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00070 · Cited by 302
Neurobiological bases of autism–epilepsy comorbidity: a focus on excitation/inhibition imbalance
Bozzi, Y., Provenzano, G., & Casarosa, S. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.13595 · Cited by 250
Silverman, J. L., Pride, M. C., Hayes, J. E., Puhger, K. R., Butler-Struben, H. M., Baker, S., & Crawley, J. N. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.66 · Cited by 215
“therapeutic target for treating some components of ASD (Blatt and Fatemi, 2011; Eagleson et al, 2010; Gaetz et al, 2014; Han et al, 2012, 2014; Harada et al, 2011; Mori et al, 2012; Oberman, 2012; Sgado et al, 2013).”
BackgroundFrye, R. E., & Rossignol, D. A. (2016) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s38337 · Cited by 96
Metadata
- Authors
- Oberman, L. M.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2012-09-26
- Volume
- 21
- Issue
- 12
- Pages
- 1819-1825
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2033554939
- Cited by
- 47
- References
- 18
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.